Vanda Pharmaceuticals price to free cash flow VNDA

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 22.6×; May 2024
8-year median: 16.2×
8-year range: 5.9× to 294×
Peer median: 11.4×

Vanda Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2024, at 22.6×.

On the days it had one over the last 8 years, its median was 16.2×, from 5.9× in Jul 2023 to 294× in Jul 2018.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	22.6×	8.2×	23.7×
2023	9.5×	5.9×	13.2×
2022	8.6×	8.0×	15.4×
2021	15.7×	15.7×	20.5×
2020	17.4×	10.1×	18.8×
2019	17.7×	12.7×	92.3×
2018	76.2×	70.7×	294×
2017	n/m a value too high to mean anything
2016	38.7×	33.3×	41.0×

Against its peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
VNDAVanda Pharmaceuticals	n/m
NATRNatures Sunshine Products	11.8×
ARVNArvinas	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
LFVNLifevantage	11.0×
ABUSArbutus Biopharma	n/m
SPROSpero Therapeutics	n/m
Peer median	11.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Vanda Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.